You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Using Mobile Devices for Neurofeedback to Reduce Opioid Use in Chronic Pain

    SBC: CrossComm, Inc.            Topic: NIDA

    Abstract One in five Americans has chronic pain. Many pharmacological pain interventions exist but increase risk of opioid use disorder (OUD). As a result, there is an urgent need for non-addictive pain treatments. One non- addictive pain treatments is neurofeedback, or electroencephalogram (EEG) biofeedback, which trains patients to regulate brain states linked to physiological relaxation. Neurof ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program

    SBC: Emocha Mobile Health Inc.            Topic: NIDA

    PROJECT SUMMARY Methadone remains a cornerstone of treatment for opioid use disorders (OUD). Daily or frequent supervised treatment with visual confirmation of ingestion (directly-observed therapy or “DOT”), is the standard of care for methadone treatment in federally licensed opioid treatment programs (OTPs) in the United States. DOT ensures adherence and mitigates the risk of medication pois ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Determination of circulation factors that mediate the health benefits of exercise in mitochondrial aging

    SBC: CYTEGEN CORP            Topic: NIA

    Project Summary/Abstract: This proposal seeks to test the hypothesis that endurance exercise stimulates the release of circulating factors that improve mitochondrial fitness. CyteGen’s goal is to identify these endogenous factors and engineer them to treat diseases in which mitochondrial dysfunction is central. These diseases include neurodegenerative and other diseases associated with aging, as ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Dianomi Therapeutics- Using Mineral Coated Microparticles as an Improved Sustained Delivery Method of Anakinra for Treatment and Prevention of Gout with a Single Injection

    SBC: Dianomi Therapeutics, Inc.            Topic: NIAMS

    Project SummaryGout is a prevalent inflammatory arthritic disease that affects 8.3 million people in the US. As current treat- ments are often inadequate, the impact of gout on the economy is a substantial burden. Gout develops when excessive levels of uric acid accumulate in tissue and form crystalline deposits in various joints, causing excru- ciating pain and inflammation. Without treatment, th ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Improving data capture in clinical research using a chatbot

    SBC: Dokbot, LLC            Topic: NLM

    PROJECT SUMMARY . Collecting complete and accurate outcome data directly from research participants is becoming increasingly important. Clinical researchers needs a cost-effective approach to capture high-quality patient-reported outcomes. Typically, data captured directly from participants is through self-administered questionnaires or through a human interviewer, each with their own advantages ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Analysis of new compounds to treat familial hypercholesterolemia

    SBC: GRUTHAN BIOSCIENCE LLC            Topic: NHLBI

    PROJECT SUMMARY The long-term goal of the current proposal is to generate a new class of small molecules to treat familial hypercholesterolemia. Familial hypercholesterolemia (FH) patients suffer from excessively high levels of Low Density Lipoprotein Cholesterol (LDL-C), which if left untreated results in death from severe cardiovascular disease. FH is caused primarily by mutations in the LDL rec ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion

    SBC: Bedrock Therapeutics, Inc.            Topic: NHLBI

    Adeno-associated virus (AAV) vectors have been successfully applied in clinical trials in patients with hemophilia. Two AAV based gene therapy drugs have been recently approved by the FDA. Luxturna has been valued at $850,000 for a one-time treatment for a rare form of blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. Gene therapy with AAV vectors has shown a potentially huge market ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Dual Excitation Catheter-delivered Laser Ultrasound Thrombolysis (DECLUT) for Deep Vein Thrombosis (DVT) Treatment

    SBC: SonoVascular, Inc.            Topic: NHLBI

    Dual Excitation Catheter-delivered Laser Ultrasound Thrombolysis (DECLUT) for Deep VeinThrombosis (DVT) TreatmentDeep-vein thrombosis (DVT), or the formation of clots in the deep veins of the legs, affects two million Americans per year. DVT can cause pulmonary embolism (PE), which is fatal in andgt;0.1 million cases annually in the US alone, presents as sudden death in 20-25% of cases. Recent inn ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Prevention of corneal transplant rejection using AAV-HLA-G combination therapy

    SBC: Bedrock Therapeutics, Inc.            Topic: NEI

    Abstract Corneal blindness is a leading cause of global blindness, with allogeneic corneal transplantation (CT) being the most common form of tissue transplantation worldwide. Though approximately 180,000 CT surgeries are carried out each year, around 12.7 million are currently awaiting a donor cornea to undergo the operation. Still, CT surgery is accompanied by a high failure rate: as many as 20 ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung

    SBC: Eldec Pharmaceuticals, Inc.            Topic: NIAID

    Hospital acquired pneumonia (HAP) is most common cause of mortality in intensive care units and the 2nd most common nosocomial infection in the US. P. aeruginosa, S. aureus (including MRSA) and other ESKAPE pathogens are common causes of HAP. The rise in antibiotic-resistant bacteria, including MRSA, further complicates the challenges of delivering effective treatments in this patient population. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government